CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Fresenius Kabi USA, LLC v. Maia Pharmaceuticals, Inc.

1:16-cv-00237

Overview

Case Number 1:16-cv-00237
Filing Date 2016-04-07
Status Terminated
Termination Date 2016-06-08
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Fresenius Kabi USA, LLC Operating Company

Represented By

2 Attorneys Listed

Brian E. Farnan

Farnan LLP

Tel: +1 (302) 777-0300
Fax: +1 (302) 777-0301

919 North Market Street, 12th Floor

Michael J. Farnan

Farnan LLP

Tel: +1 (302) 777-0338
Fax: +1 (302) 421-5870

919 North Market Street, 12th Floor

Counter Claimant

Maia Pharmaceuticals, Inc. Operating Company

Represented By

5 Attorneys Listed

Thomas P. Krzeminski

Email: Thomas.Krzeminski@knobbe.com

Karen M. Cassidy

Email: karen.cassidy@knobbe.com

Jayadeep R. Deshmukh

Email: jdeshmukh@kasowitz.com

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials 3 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 3 U.S. Courts: 3
USPTO PTAB Trial 2017-01-19
IPR2017-00645

Mylan Institutional Inc. v. Fresenius Kabi USA, LLC

U.S. Continuation Sibling (9006289)
Status: Terminated-Settled
USPTO PTAB Trial 2017-01-19
IPR2017-00644

Mylan Institutional Inc. v. Fresenius Kabi USA LLC

U.S. Continuation Sibling (9168239)
Status: Terminated-Settled
USPTO PTAB Trial 2017-01-19
IPR2017-00643

Mylan Institutional Inc. v. Fresenius Kabi USA, LLC

Asserted Patent
Status: Terminated-Settled
U.S. District Court 2016-06-09
1:16-cv-03315

Fresenius Kabi USA, LLC v. Maia Pharmaceuticals, Inc.

Asserted Patent
Status: NJD
U.S. District Court 2016-06-09
1:16-cv-03316

Fresenius Kabi USA, LLC v. Dr. Reddys Laboratories, Inc.

Asserted Patent
Status: NJD
U.S. District Court 2016-03-17
1:16-cv-00169

Fresenius Kabi USA, LLC v. Dr. Reddys Laboratories, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9006289
Levothyroxine formulations
Filed: 2012-08-29
Issued: 2015-04-14
Active (5.9 yrs remaining) +35d PTA
Expires: 2032-10-03
US9168238
Levothyroxine formulations
Filed: 2015-03-08
Issued: 2015-10-27
Active (8.3 yrs remaining)
Expires: 2035-03-08
US9168239
Levothyroxine formulations
Filed: 2015-03-13
Issued: 2015-10-27
Active (8.3 yrs remaining)
Expires: 2035-03-13

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

11

Dispositive

11

Granted

0

Denied

0

Pending / Review

11

Motions by Category

Motion to Transfer Venue (28 U.S.C. Β§ 1404) 8 Motion to Dismiss 3

Key Dispositive Motions & Rulings

Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
ORDER - Granting Motion to Transfer Case to District of New Jersey ( 15 ) filed by Maia Pharmaceuticals, Inc. Signed by Judge Gregory M. Sleet on 6/8/2016. (mdb...
Entry #28 • 2016-06-08 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss Based upon Defendant's Counterclaims for Inequitable Conduct - filed by Fresenius Kabi USA, LLC. (Farnan, Brian) (Entered: 06/06/2016)
Entry #25 • 2016-06-06 Document →
Motion to Dismiss Pending / Under Review
OPENING BRIEF in Support re 25 MOTION to Dismiss Based upon Defendant's Counterclaims for Inequitable Conduct filed by Fresenius Kabi USA, LLC.Answering Brief/R...
Entry #26 • 2016-06-06 Document →
Motion to Dismiss Pending / Under Review
DECLARATION of Brian E. Farnan re 25 Motion to Dismiss Based upon Defendant's Counterclaims for Inequitable Conduct by Fresenius Kabi USA, LLC. (Attachments: # ...
Entry #27 • 2016-06-06 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
ANSWERING BRIEF in Opposition re 15 MOTION to Transfer Case to District of New Jersey filed by Fresenius Kabi USA, LLC.Reply Brief due date per Local Rules is 6...
Entry #23 • 2016-06-01 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
STIPULATION TO EXTEND TIME (i) for Plaintiff to file an Answering Brief in Response to Defendant's Motion to Transfer and (ii) for Plaintiff to Respond to Defen...
Entry #21 • 2016-05-19 Document →

Docket Entries

(41 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Maia Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1909135.) - filed by Fresenius Kabi USA, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(nmb) (Entered: 04/07/2016)

Entry #1 • 2016-04-07
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 04/07/2016)

Entry #2 • 2016-04-07
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/24/2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 8/24/2018. (nmb) (Entered: 04/07/2016)

Entry #3 • 2016-04-07
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,006,289 B2; US 9,168,238 B2; US 9,168,239 B2. (nmb) (Entered: 04/07/2016)

Entry #4 • 2016-04-07
1

Summons Issued

Entry #5 • 2016-04-07
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc